# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst David Anderson downgrades Aspen Aerogels (NYSE:ASPN) from Equal-Weight to Underweight and lowers the price ...
Canaccord Genuity analyst George Gianarikas maintains Aspen Aerogels (NYSE:ASPN) with a Buy and lowers the price target from...
Second Half of 2025 Financial OutlookAspen's second half of 2025 Outlook is as follows:($ in millions, except per share amo...
Aspen Aerogels (NYSE:ASPN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) ...
Barclays analyst David Anderson downgrades Aspen Aerogels (NYSE:ASPN) from Overweight to Equal-Weight and lowers the price t...
Aspen Aerogels (NYSE:ASPN) is looking for Q2 GAAP EPS of $(0.13)-$(0.05) vs $0.01 analyst estimate. sees sales of $70.000 milli...